BCRX Q3 2018 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-83.4% YoY

Gross Profit

$1M98.8% margin

Operating Income

-$28M-1959.6% margin

Net Income

-$30M-2035.6% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

-88.4%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$35M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$168M

Total Liabilities

$95M

Stockholders' Equity

$73M

Cash & Equivalents

$53M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$9M	-83.4%
Gross Profit	$1M	$8M	-80.9%
Operating Income	-$28M	-$13M	-113.4%
Net Income	-$30M	-$15M	-95.6%

Revenue Segments

Collaborative and Other Research and Development

$931,00064%

Royalty

$523,00036%